Search the evidence

Find the signal.

Search titles, impact clusters, countries, organizations and the full text of every analysis.

2 stories found

A strand of artificial intelligence code becomes a bacteriophage above a laboratory petri dish, marking the transition from digital design to living replication.
Social good & healthUnited States+4 clusters01

Scientists used AI to design viable viruses. The safety boundary just crossed into biology

Scientists used genome language models to design 16 viable bacteriophages that infected and killed the bacterium E coli in laboratory tests. The New York Times reports the peer-reviewed publication of work in which researchers generated thousands of candidate genomes, synthesized 285 designs, and identified 16 functional phages. These are viruses that target bacteria, not humans; Arc Institute says the models excluded eukaryotic viruses from training and the working phages showed restricted host range in testing. The result is both a therapeutic opportunity and a dual-use warning. AI-assisted phage design could help attack antibiotic-resistant bacteria, but it also proves that generative output can become a replicating biological system once synthesis and experimentation enter the chain.

5 min
Several luminous designed protein binders attach to a transparent molecular target above a physical laboratory assay tray.
Social good & healthGlobal+4 clusters02

Claude designs protein binders that survive wet-lab testing

Anthropic reports that Claude Opus 4.8 and Mythos Preview designed protein binders against 15 targets and succeeded against 14 after external laboratories produced and tested the designs. Reported hit rates ranged from 22.6 percent to 35.1 percent depending on the setup, above the 10 to 15 percent that Anthropic says is typical in current campaigns. The models orchestrated existing protein-design and folding tools with minimal human scientific guidance, producing 354 confirmed binders from 1,320 designs. This is a meaningful result because physical testing separates a scientific claim from a plausible-looking output. It is not a finished drug. Minibinders are an early design step, one target failed, additional characterization is planned, and the campaigns used substantial compute and specialist infrastructure. The same autonomy is dual-use, so Anthropic says its strongest biological capabilities remain restricted while it develops scientist access. The breakthrough and the control problem arrive together.

7 min